Journal Article
. 2009 Dec;374(9707).
doi: 10.1016/S0140-6736(09)61523-3.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Kathy S Albain 1 William E Barlow 2 Peter M Ravdin 3 William B Farrar 4 Gary V Burton 5 Steven J Ketchel 6 Charles D Cobau 7 Ellis G Levine 8 James N Ingle 9 Kathleen I Pritchard 10 Allen S Lichter 11 Daniel J Schneider 12 Martin D Abeloff 13 I Craig Henderson 14 Hyman B Muss 15 Stephanie J Green 2 Danika Lew 2 Robert B Livingston 6 Silvana Martino 16 C Kent Osborne 17 Breast Cancer Intergroup of North America  
Affiliations
  • PMID: 20004966
  •     23 References
  •     71 citations

Abstract

Background: Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy.

Methods: We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT). Overall survival and toxicity were predefined, important secondary outcomes for each objective. Patients in this open-label trial were randomly assigned by a computer algorithm in a 2:3:3 ratio (tamoxifen:CAF-T:CAFT) and analysis was by intention to treat of eligible patients. Groups were compared by stratified log-rank tests, followed by Cox regression analyses adjusted for significant prognostic factors. This trial is registered with ClinicalTrials.gov, number NCT00929591.

Findings: Of 1558 randomised women, 1477 (95%) were eligible for inclusion in the analysis. After a maximum of 13 years of follow-up (median 8.94 years), 637 women had a disease-free survival event (tamoxifen, 179 events in 361 patients; CAF-T, 216 events in 566 patients; CAFT, 242 events in 550 patients). For the first objective, therapy with the CAF plus tamoxifen groups combined (CAFT or CAF-T) was superior to tamoxifen alone for the primary endpoint of disease-free survival (adjusted Cox regression hazard ratio [HR] 0.76, 95% CI 0.64-0.91; p=0.002) but only marginally for the secondary endpoint of overall survival (HR 0.83, 0.68-1.01; p=0.057). For the second objective, the adjusted HRs favoured CAF-T over CAFT but did not reach significance for disease-free survival (HR 0.84, 0.70-1.01; p=0.061) or overall survival (HR 0.90, 0.73-1.10; p=0.30). Neutropenia, stomatitis, thromboembolism, congestive heart failure, and leukaemia were more frequent in the combined CAF plus tamoxifen groups than in the tamoxifen-alone group.

Interpretation: Chemotherapy with CAF plus tamoxifen given sequentially is more effective adjuvant therapy for postmenopausal patients with endocrine-responsive, node-positive breast cancer than is tamoxifen alone. However, it might be possible to identify some subgroups that do not benefit from anthracycline-based chemotherapy despite positive nodes.

Funding: National Cancer Institute (US National Institutes of Health).

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A Goldhirsch, J H Glick, +4 authors, Panel members.
Ann Oncol, 2005 Sep 09; 16(10). PMID: 16148022
Highly Cited.
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG).
J Natl Cancer Inst, 2002 Jul 18; 94(14). PMID: 12122096
Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.
V Hug, G N Hortobagyi, B Drewinko, M Finders.
J Clin Oncol, 1985 Dec 01; 3(12). PMID: 4067614
Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
F J Cummings, R Gelman, J Horton.
J Clin Oncol, 1985 Jul 01; 3(7). PMID: 3894587
Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro.
G J Goldenberg, E K Froese.
Biochem Pharmacol, 1985 Mar 15; 34(6). PMID: 3977953
Designs for group sequential tests.
T R Fleming, D P Harrington, P C O'Brien.
Control Clin Trials, 1984 Dec 01; 5(4). PMID: 6518769
Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.
R L Sutherland, M D Green, +2 authors, I W Taylor.
Eur J Cancer Clin Oncol, 1983 May 01; 19(5). PMID: 6683633
Combined chemo-hormonal therapy in breast cancer: a hypothesis.
C K Osborne.
Breast Cancer Res Treat, 1981 Jan 01; 1(2). PMID: 7348568
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
J M Bull, D C Tormey, +5 authors, R Simon.
Cancer, 1978 May 01; 41(5). PMID: 348293
Evaluation of survival data and two new rank order statistics arising in its consideration.
N Mantel.
Cancer Chemother Rep, 1966 Mar 01; 50(3). PMID: 5910392
Highly Cited.
Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
B Fisher, C Redmond, +7 authors, S Legault-Poisson.
J Clin Oncol, 1989 May 01; 7(5). PMID: 2651576
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.
C K Osborne, L Kitten, C L Arteaga.
J Clin Oncol, 1989 Jun 01; 7(6). PMID: 2715802
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
B Fisher, C Redmond, +7 authors, A G Glass.
J Clin Oncol, 1990 Jun 01; 8(6). PMID: 2189950
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
S E Rivkin, S Green, +7 authors, C K Osborne.
J Clin Oncol, 1994 Oct 01; 12(10). PMID: 7931477
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
M Perloff, L Norton, +11 authors, J F Holland.
J Clin Oncol, 1996 May 01; 14(5). PMID: 8622076
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
K I Pritchard, A H Paterson, +19 authors, R A Buckman.
J Clin Oncol, 1997 Jun 01; 15(6). PMID: 9196144
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
M N Levine, V H Bramwell, +15 authors, D Tu.
J Clin Oncol, 1998 Aug 15; 16(8). PMID: 9704715
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
Early Breast Cancer Trialists' Collaborative Group.
N Engl J Med, 1988 Dec 29; 319(26). PMID: 3205265
Highly Cited.
Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute.
A U Buzdar, G N Hortobagyi, +3 authors, E A Gehan.
NCI Monogr, 1986 Jan 01; (1). PMID: 3534594
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P Eifel, J A Axelson, +11 authors, D Roter.
J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563
Highly Cited. Review.
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
D Crivellari, M Bonetti, +18 authors, A Goldhirsch.
J Clin Oncol, 2000 Mar 29; 18(7). PMID: 10735888
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Takahiro Nakayama, Shinzaburo Noguchi.
Oncologist, 2010 Jan 19; 15(1). PMID: 20080863    Free PMC article.
Review.
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Hirokuni Ikeda, Naruto Taira, +8 authors, Shinichiro Miyoshi.
Breast Cancer Res, 2010 Jun 29; 12(3). PMID: 20579400    Free PMC article.
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.
Pelagia G Tsoutsou, Yazid Belkacemi, +5 authors, Association of Radiotherapy and Oncology in the Mediterranean area (AROME).
Oncologist, 2010 Nov 03; 15(11). PMID: 21041378    Free PMC article.
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Primo N Lara, Jeff Longmate, +11 authors, David R Gandara.
Clin Lung Cancer, 2011 Jan 29; 12(1). PMID: 21273177    Free PMC article.
Measuring the performance of markers for guiding treatment decisions.
Holly Janes, Margaret S Pepe, Patrick M Bossuyt, William E Barlow.
Ann Intern Med, 2011 Feb 16; 154(4). PMID: 21320940    Free PMC article.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Targeting IGF-1R: at a crossroad.
Adrian V Lee, Douglas Yee.
Oncology (Williston Park), 2011 Jul 02; 25(6). PMID: 21717908    Free PMC article.
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Davide Bedognetti, Mario Roberto Sertoli, +12 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2011 Sep 17; 103(20). PMID: 21921285    Free PMC article.
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
H Wong, S Lau, +6 authors, T Yau.
Med Oncol, 2011 Oct 11; 29(3). PMID: 21983862
Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.
Amit Khatri, Richard C Brundage, +3 authors, Mark N Kirstein.
AAPS J, 2011 Nov 22; 14(1). PMID: 22101930    Free PMC article.
Beyond castration-defining future directions in the hormonal treatment of prostate cancer.
Saroj Niraula, Kim Chi, Anthony Michael Joshua.
Horm Cancer, 2011 Nov 30; 3(1-2). PMID: 22124843
Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.
Toru Mukohara.
Chemother Res Pract, 2012 Feb 02; 2011. PMID: 22295205    Free PMC article.
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
Zhinong Jiang, Junlan Guo, +3 authors, Linbo Wang.
J Exp Clin Cancer Res, 2012 May 05; 31. PMID: 22553917    Free PMC article.
Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?
Jeffrey G Schneider, Danny N Khalil.
Breast Cancer Res Treat, 2012 Jun 23; 134(3). PMID: 22723033    Free PMC article.
Combinatorial drug therapy for cancer in the post-genomic era.
Bissan Al-Lazikani, Udai Banerji, Paul Workman.
Nat Biotechnol, 2012 Jul 12; 30(7). PMID: 22781697
Highly Cited. Review.
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
William B Wong, Scott D Ramsey, +2 authors, David L Veenstra.
Contemp Clin Trials, 2012 Sep 18; 33(6). PMID: 22981891    Free PMC article.
Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer.
Kenny A Rodriguez-Wallberg, Kutluk Oktay.
Oncologist, 2012 Sep 26; 17(11). PMID: 23006497    Free PMC article.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.
M B Hannouf, M Brackstone, B Xie, G S Zaric.
Curr Oncol, 2012 Nov 13; 19(5). PMID: 23144580    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.
R Leibowitz-Amit, A M Joshua.
Curr Oncol, 2013 Jan 29; 19(Suppl 3). PMID: 23355790    Free PMC article.
Developing safety criteria for introducing new agents into neoadjuvant trials.
Angela DeMichele, Donald A Berry, +22 authors, Laura Esserman.
Clin Cancer Res, 2013 Mar 09; 19(11). PMID: 23470967    Free PMC article.
Review.
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Debu Tripathy, Peter A Kaufman, +6 authors, Hope S Rugo.
Oncologist, 2013 May 09; 18(5). PMID: 23652380    Free PMC article.
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
Roman Rouzier, Paolo Pronzato, +3 authors, William J Valentine.
Breast Cancer Res Treat, 2013 Jun 01; 139(3). PMID: 23722312    Free PMC article.
Systematic Review.
Molecular profiling for breast cancer: a comprehensive review.
Muaiad Kittaneh, Alberto J Montero, Stefan Glück.
Biomark Cancer, 2013 Nov 20; 5. PMID: 24250234    Free PMC article.
Review.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.
Arturo Loaiza-Bonilla, Francisco Socola, Stefan Glück.
Clin Med Insights Womens Health, 2013 Jan 01; 6. PMID: 24665209    Free PMC article.
Review.
An approach to evaluating and comparing biomarkers for patient treatment selection.
Holly Janes, Marshall D Brown, Ying Huang, Margaret S Pepe.
Int J Biostat, 2014 Apr 04; 10(1). PMID: 24695044    Free PMC article.
Combining biomarkers to optimize patient treatment recommendations.
Chaeryon Kang, Holly Janes, Ying Huang.
Biometrics, 2014 Jun 04; 70(3). PMID: 24889663    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
Genome-based risk prediction for early stage breast cancer.
Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187476    Free PMC article.
Review.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Hyun Ae Jung, Yeon Hee Park, +10 authors, Young-Hyuck Im.
Tumour Biol, 2014 Oct 20; 36(2). PMID: 25326808
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Alan P Venook, Maria E Arcila, +15 authors, Marian L Birkeland.
J Natl Compr Canc Netw, 2014 Nov 02; 12(11). PMID: 25361808    Free PMC article.
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
L Bazzola, C Foroni, +20 authors, D Generali.
Br J Cancer, 2014 Dec 03; 112(1). PMID: 25461806    Free PMC article.
Expression of integrin-binding protein Nischarin in metastatic breast cancer.
Jie Chen, Wei-Liang Feng, +2 authors, Shang-Nao Xie.
Mol Med Rep, 2015 Feb 20; 12(1). PMID: 25695373    Free PMC article.
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Halle C F Moore, Joseph M Unger, +22 authors, POEMS/S0230 Investigators.
N Engl J Med, 2015 Mar 05; 372(10). PMID: 25738668    Free PMC article.
Highly Cited.
Challenges and Potential for Ovarian Preservation with SERMs.
Alison Y Ting, Brian K Petroff.
Biol Reprod, 2015 Mar 27; 92(5). PMID: 25810474    Free PMC article.
Review.
Tamoxifen prevents apoptosis and follicle loss from cyclophosphamide in cultured rat ovaries.
Joanna Piasecka-Srader, Fernando F Blanco, +4 authors, Brian K Petroff.
Biol Reprod, 2015 Apr 03; 92(5). PMID: 25833159    Free PMC article.
Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New.
Eunpi Cho, Ann K Schwemm, +7 authors, Vijayakrishna K Gadi.
Clin Breast Cancer, 2015 May 31; 15(5). PMID: 26025883    Free PMC article.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
Holly Janes, Marshall D Brown, Margaret S Pepe.
Stat Med, 2015 Jun 27; 34(27). PMID: 26112650    Free PMC article.
Application status of tamoxifen in endocrine therapy for early breast cancer.
Qiancheng Hu, Ting Luo, +3 authors, Hong Zheng.
Exp Ther Med, 2015 Jul 03; 9(6). PMID: 26136961    Free PMC article.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Concurrent or Sequential Hormonal and Radiation Therapy in Breast Cancer: A Literature Review.
Matthew J Cecchini, Edward Yu, +2 authors, Michael Lock.
Cureus, 2015 Dec 02; 7(10). PMID: 26623219    Free PMC article.
Review.
Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.
Amar U Kishan, Susan A McCloskey.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753007    Free PMC article.
Review.
Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients.
Hee Jeong Kim, Tae-In Yoon, +8 authors, Sei Hyun Ahn.
J Breast Cancer, 2016 Jan 16; 18(4). PMID: 26770243    Free PMC article.
Approaches to modernize the combination drug development paradigm.
Daphne Day, Lillian L Siu.
Genome Med, 2016 Oct 30; 8(1). PMID: 27793177    Free PMC article.
Review.
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Joachim Diessner, Manfred Wischnewsky, +8 authors, Achim Wöckel.
PLoS One, 2016 Dec 20; 11(12). PMID: 27992550    Free PMC article.
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Matthew J Ellis, Vera J Suman, +28 authors, Kelly Hunt.
J Clin Oncol, 2017 Jan 04; 35(10). PMID: 28045625    Free PMC article.
Highly Cited.
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Rebecca L Glaser, Anne E York, Constantine Dimitrakakis.
Menopause, 2017 Feb 15; 24(7). PMID: 28195993    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population.
Joseph M Unger, Michael LeBlanc, Charles D Blanke.
JAMA Oncol, 2017 Jun 07; 3(10). PMID: 28586789    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Learning from big data: are we undertreating older women with high-risk breast cancer?
Joseph A Sparano, Hyman Muss.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721380    Free PMC article.
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel.
Chengcheng Gong, Zhongyi Yang, +9 authors, Yingjian Zhang.
Sci Rep, 2017 Jul 28; 7(1). PMID: 28747642    Free PMC article.
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.
Holly Janes, Marshall D Brown, +2 authors, William E Barlow.
Contemp Clin Trials, 2017 Aug 19; 63. PMID: 28818434    Free PMC article.
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
Scott M Belcher, Caleb C Burton, +4 authors, Kathleen E Wray.
BMC Pharmacol Toxicol, 2017 Sep 08; 18(1). PMID: 28877739    Free PMC article.
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
M M Regan, B A Walley, +15 authors, O Pagani.
Ann Oncol, 2017 Sep 16; 28(9). PMID: 28911092    Free PMC article.
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Takahiro Nakayama, Yasuaki Sagara, +8 authors, Shinzaburo Noguchi.
Cancer Chemother Pharmacol, 2018 Feb 23; 81(4). PMID: 29468454    Free PMC article.
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Yun Yeong Kim, Se Jeong Oh, +2 authors, Heung Kyu Park.
PLoS One, 2018 Jul 07; 13(7). PMID: 29979736    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
The Warwick Experience of the Oncotype DX® Breast Recurrence Score® Assay as a Predictor of Chemotherapy Administration.
Mashuk Alam Khan, Laura Henderson, +2 authors, Lucie Jones.
Breast Care (Basel), 2018 Dec 01; 13(5). PMID: 30498424    Free PMC article.
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Wendy A Woodward, William E Barlow, +15 authors, Kathy S Albain.
JAMA Oncol, 2020 Jan 10; 6(4). PMID: 31917424    Free PMC article.
Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.
Clara Taubenhansl, Olaf Ortmann, +2 authors, Monika Klinkhammer-Schalke.
Arch Gynecol Obstet, 2019 Nov 22; 301(2). PMID: 31749031    Free PMC article.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings.
Joseph M Unger, Charles D Blanke, +4 authors, Dawn L Hershman.
JAMA Netw Open, 2020 May 01; 3(4). PMID: 32352530    Free PMC article.
Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study.
Hanwen Zhang, Ning Zhang, +2 authors, Qifeng Yang.
Ther Adv Med Oncol, 2021 Jan 12; 12. PMID: 33425023    Free PMC article.
The role of gonadotropin-releasing hormone agonists in female fertility preservation.
Jae Hoon Lee, Young Sik Choi.
Clin Exp Reprod Med, 2021 Mar 02; 48(1). PMID: 33648041    Free PMC article.